Depodrag®

Injectable suspension.

Steroidal anti-inflammatory.

Dogs and cats.

Each 1 mL of suspension contains:
Triamcinolone Acetonide…………. 6 mg
Excipients c.s.p………………………. 1 mL

Depot anti-inflammatory for allergic, dermatological and arthritis disorders.

Dogs and cats:

• In cases of allergy: 0.2 mg/kg, in a single dose. In severe cases, up to 1 mg/kg may be administered in a single dose.
• For intra-articular and intrasynovial treatment: 1 to 3 mg/kg in a single dose, repeated if necessary after 3 to 4 days.

Dogs and cats:

• In cases of allergy: 0.2 mL per 6 kg of body weight in a single dose. In severe cases, up to 1 mL per 6 kg of body weight can be administered in a single dose.
• For intra-articular and intra-synovial treatment: 0.2 to 0.5 mL as a single dose, repeated if necessary after 3 to 4 days.

It is not advisable to repeat the treatment more than three consecutive times.

Intramuscular, subcutaneous, intra-articular and intrasynovial.

Long-term use of Depodrag^® may cause suppressive effects on the hypothalamic-pituitary-adrenal axis leading to adrenal atrophy (adrenal insufficiency). It can also cause bone resorption or inhibition of bone growth and repair, inhibition of collagen synthesis, decreased growth rate, delayed healing, diarrhea, gastrointestinal irritation, gastrointestinal ulceration, hematopoietic changes, sodium and fluid retention, and recrudescence of latent infections.
The most common side effects are polyuria, polydipsia, polyphagia, lethargy, weakness and bilateral alopecia. Less common are weight loss, anorexia, and diarrhea.

• In bacterial infections, the use should be associated with antibacterials.
• Corticosteroids can precipitate labor during late gestation.
• Shake before use.
• Keep out of reach of children and pets.

• Do not use in viral infectious processes and generalized fungal infections.
• Do not use in musculoskeletal disorders where immobility is required.
• Do not use in animals with tuberculosis, chronic nephritis, or Cushing’s syndrome, except for emergency therapy.
• Do not use in case of bone metaplasia and osteoporosis.
• Do not use in patients with diabetes mellitus, renal or heart failure.
• Do not use in patients with hypersensitivity to the active substance.
• Do not use in animals with gastrointestinal or corneal ulcer.
• Do not use in pregnant or lactating females.

• Do not use in pregnant and lactating females.
• Glucocorticoids are probably needed for normal fetal development. They may be required for proper surfactant production and development of myelin, retina, pancreas, and breasts.
• Excessive doses early in gestation can lead to teratogenic effects. Administration of exogenous steroids may induce labor when used in late pregnancy. It is recommended not to use high doses in pregnant animals.
• Glucocorticoids not bound to plasma proteins enter the milk. High doses, or prolonged administration in mothers, can potentially inhibit the growth of newborns.

• Amphotericin B or caliuretic diuretics (furosemide, thiazides) may cause hypokalemia when administered concomitantly with glucocorticoids. When these drugs are used concurrently with digitalis glycosides, the possibility of toxicity may increase if hypokalemia occurs. Diligent monitoring of potassium and digitalis levels is recommended.
• Glucocorticoids can reduce blood levels of salicylates.
• Insulin requirements may be increased in patients receiving glucocorticoids.
• Phenytoin, Phenobarbital, Rifampicin may increase glucocorticoid metabolism.
• Concomitant administration of glucocorticoids and cyclosporine may increase blood levels of each, with mutual inhibition of hepatic metabolism. The clinical significance of this interaction is uncertain. Glucocorticoids may also inhibit hepatic metabolism of cyclophosphamide. Dosage adjustments may be required.
• Mitotane can alter steroid metabolism; Higher than usual doses may be needed to treat mitotane-induced adrenal insufficiency.
• Patients treated with corticosteroids at immunosuppressive doses should not receive live attenuated live virus vaccines because viral replication may be enhanced. A diminished immune response may occur after administration of a vaccine, toxoid, or bacterin, in patients receiving glucocorticoids.
• Administration of ulcerogenic drugs (e.g., nonsteroidal anti-inflammatory drugs) with glucocorticoids may increase the risk of gastrointestinal ulceration.
• The effects of hydrocortisone, and possibly other glucocorticoids, may be potentiated by concomitant administration with estrogens.
• In patients with myasthenia gravis, concomitant administration of glucocorticoids and anticholinesterases (e.g., pyridostigmine, neostigmine, etc.) may induce pronounced muscle weakness. If possible, discontinue anticholinesterase medication at least 24 hours before glucocorticoid administration

The product is irritating in the case of contact with eyes. It can be dangerous in the case of accidental ingestion and in the case of skin contact.
Pregnant women should not handle the product.

Dispose of unused product residues in their original packaging. Dispose of waste of this product with caution along with household waste.
Uruguay: Dispose of the product container at the nearest collection center.

Store at a temperature between 2° and 30°C, away from light.
Once opened, use within 3 months. Discard the unused product after that period of time.
Uruguay: Dispose of the product container at the nearest collection center.

Sale by prescription to the Veterinary Doctor.

Ampoule bottle with 5 mL and 20 mL

Chile: Reg. SAG No 529
Uruguay: Reg. MGAP N° A-4493
Rep. Dominican: Reg. No 5607
Bolivia: Reg. SENASAG PUV-F-N° 005515/13
Peru: Reg. SENASA F.06.42.I.0240

Laboratorio Drag Pharma Chile Invetec S.A.
Lautaro N° 300. Quilicura. Santiago. Chile.